In Gal-1-overexpressing hepatocellular carcinoma (HCC), the novel Gal-1 inhibitor OTX008 compensated the downregulated negative regulator of Gal-1 miR-22, blocking cell growth and reducing tumour size, in combination with the angiogenesis inhibitor sorafenib (33). This evidence concerns the gene LGALS1 and neoplasm.